---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-354793"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2026-08-18T13:03:53+00:00"
generated_at: "2026-08-18T13:05:57.450397+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "medium"
source: SEC EDGAR
---

# Amylyx announces positive topline Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia

## Summary
- Positive topline results announced Aug 18, 2026 from LUCIDITY Phase 3 trial of avexitide in post-bariatric hypoglycemia (PBH).
- Trial enrolled participants with PBH following Roux-en-Y gastric bypass surgery; no efficacy numbers disclosed in filing text.
- Investor conference call and slide deck (Exhibit 99.1) held same day; detailed endpoint data not included in available excerpt.
- Avexitide is Amylyx's (AMLX) candidate for PBH; positive readout could support registration pathway.

## SEC filing metadata
- accession: 0001193125-26-354793
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2026-08-18T13:03:53+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312526354793/0001193125-26-354793-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312526354793/d184004d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-354793
- JSON: https://secwatch.observer/filing/0001193125-26-354793.json
- Plain text: https://secwatch.observer/filing/0001193125-26-354793.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.